lunes, 29 de octubre de 2012

Feasibility evaluation of an online tool to guide... [Fam Cancer. 2012] - PubMed - NCBI

Feasibility evaluation of an online tool to guide... [Fam Cancer. 2012] - PubMed - NCBI


Fam Cancer. 2012 Oct 21. [Epub ahead of print]


Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.





Source


Departments of Medicine and of Health Research and Policy, Stanford University School of Medicine, HRP Redwood Building, Room T254A, Stanford, CA, 94305-5405, USA.



Abstract


Women with BRCA1 or BRCA2 (BRCA1/2) mutations face difficult decisions about managing their high risks of breast and ovarian cancer. We developed an online tool to guide decisions about cancer risk reduction (available at: http://brcatool.stanford.edu ), and recruited patients and clinicians to test its feasibility. We developed questionnaires for women with BRCA1/2 mutations and clinicians involved in their care, incorporating the System Usability Scale (SUS) and the Center for Healthcare Evaluation Provider Satisfaction Questionnaire (CHCE-PSQ). We enrolled BRCA1/2 mutation carriers who were seen by local physicians or participating in a national advocacy organization, and we enrolled clinicians practicing at Stanford University and in the surrounding community. Forty BRCA1/2 mutation carriers and 16 clinicians participated. Both groups found the tool easy to use, with SUS scores of 82.5-85 on a scale of 1-100; we did not observe differences according to patient age or gene mutation. General satisfaction was high, with a mean score of 4.28 (standard deviation (SD) 0.96) for patients, and 4.38 (SD 0.89) for clinicians, on a scale of 1-5. Most patients (77.5 %) were comfortable using the tool at home. Both patients and clinicians agreed that the decision tool could improve patient-doctor encounters (mean scores 4.50 and 4.69, on a 1-5 scale). Patients and health care providers rated the decision tool highly on measures of usability and clinical relevance. These results will guide a larger study of the tool's impact on clinical decisions.


PMID:

23086584
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario